Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis. J of Skin. 2020;4(6):s98. doi:10.25251/skin.4.supp.98